| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Substance P 1-9 targets the neurokinin-1 receptor (NK1R), the primary receptor for substance P. As a fragment of substance P, it interacts with the substance P signaling pathway. The compound decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder, but has no significant effects on bradykinin or SP-(6-11). Its mechanism of action involves modulating substance P availability and signaling.
|
|---|---|
| ln Vitro |
The nonapeptide substance (1–9) decreases substance P's inactivation in the ileum and bladder of guinea pigs, but it has no discernible effect on bradykinin or SP–(6–11) [1].
In vitro, Substance P (1-9) decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder, but has no significant effects on bradykinin or SP-(6-11). As a nonapeptide fragment, its activity is characterized in tissue-based assays measuring smooth muscle contraction and neurotransmitter inactivation. The compound's effects on substance P metabolism have been studied in various in vitro systems. |
| ln Vivo |
In vivo activity of Substance P (1-9) is inferred from its role as a substance P fragment that modulates substance P signaling. As a neuropeptide involved in pain, inflammation, and stress responses, the compound may have effects on these physiological processes. However, detailed in vivo data for Substance P (1-9) are limited in the available literature. The compound is a research tool for studying substance P biology.
|
| Enzyme Assay |
The in vitro tissue assay for Substance P (1-9) typically involves using guinea-pig ileum or urinary bladder preparations. Tissue strips are mounted in organ baths containing physiological buffer at 37degC with continuous oxygenation. Substance P (1-9) is added at varying concentrations (typically 0.001-100 uM), and tissue contraction is measured using force transducers. The compound's ability to decrease substance P inactivation is assessed by measuring the duration or magnitude of substance P-induced contractions in the presence or absence of Substance P (1-9). The specificity of the effect is confirmed by testing against bradykinin or SP-(6-11).
|
| Cell Assay |
In vitro cellular assays for Substance P (1-9) are conducted using cell lines expressing the neurokinin-1 receptor (NK1R), such as neuronal or immune cells. Cells are seeded in multi-well plates and treated with varying concentrations of Substance P (1-9) (typically 0.001-100 uM) in the presence or absence of substance P. Receptor activation is assessed by measuring intracellular calcium mobilization using fluorescent calcium indicators (e.g., Fluo-4), or by measuring downstream signaling pathways including MAPK and NF-kappaB activation by Western blotting or reporter gene assays. The compound's effects on substance P-induced signaling are determined by comparing responses in treated and untreated cells.
|
| Animal Protocol |
In vivo animal studies for Substance P (1-9) are not extensively documented. As a research tool for studying substance P biology, typical studies would involve administration to rodents to assess its effects on pain, inflammation, or stress responses. The compound would be administered by intracerebroventricular, intrathecal, or intravenous injection at doses determined from preliminary studies. Behavioral tests such as the formalin test or tail-flick test might be performed to assess pain responses. Inflammatory markers would be measured in plasma or tissue samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Substance P (1-9) are characteristic of a peptide. The compound has a molecular weight of approximately 1000 g/mol. As a peptide, it is expected to have limited oral bioavailability and a short half-life due to rapid proteolytic degradation. The compound is typically administered by injection in research studies. It should be stored as a powder at -20degC for up to 3 years and in solution at -80degC for up to 1 year. The compound should be kept away from moisture.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Substance P (1-9) is characteristic of a neuropeptide fragment. As a research compound, it is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling peptides in a laboratory setting. No specific LD50 values have been reported. The compound's effects on pain and inflammation are dose-dependent and related to its modulation of substance P signaling.
|
| References | |
| Additional Infomation |
Substance P (1-9) (CAS 57468-17-4) is a nonapeptide fragment of the full-length neuropeptide Substance P (SP, 1-11). It belongs to the tachykinin family and plays a role in pain, inflammation, and stress responses. The compound decreases substance P inactivation in the guinea-pig ileum and urinary bladder. It is a research tool for studying substance P biology and is available for research purposes only.
|
| Molecular Formula |
C52H77N15O12
|
|---|---|
| Molecular Weight |
1104.26108
|
| Exact Mass |
1103.59
|
| CAS # |
57468-17-4
|
| PubChem CID |
189167
|
| Appearance |
White to off-white solid powder
|
| Density |
1.46 g/cm3
|
| Index of Refraction |
1.674
|
| LogP |
2.542
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
33
|
| Heavy Atom Count |
79
|
| Complexity |
2130
|
| Defined Atom Stereocenter Count |
8
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~22.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9056 mL | 4.5279 mL | 9.0558 mL | |
| 5 mM | 0.1811 mL | 0.9056 mL | 1.8112 mL | |
| 10 mM | 0.0906 mL | 0.4528 mL | 0.9056 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
